Kodiak Sciences Inc KOD

$99.18 -1.22 (-1.22%)

Valuation

Market cap
6,233,363,000
Revenue TTM
$0
Net income TTM
$-229,970,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
568,000
Avg volume
2,028,656
Day's range
$96.58 – $100.69
Shares out
62,849,000
Stochastic %K
78%
Beta
2.03
Analysts
Moderate Buy
Price target
$118.00

Price

Company profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical stu...

Show more

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 281 0850
Website
https://kodiak.com
Address
1250 Page Mill Road, Palo Alto, United States

Latest news

Stocktwits

Merlintrader Oct 31, 12:39 PM
$KOD closed the week at $99.18 (+13.2% w/w, -1.2% Friday), above the 50-day SMA ($63.72) and above the 200-day ($42.09). RSI14 66.5. Support $79.06, resistance $103.73 (20-day range, top). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/kodiak-sciences-stock-hub/
0 replies
Stekli27 Oct 30, 8:44 PM
$KOD 100✅ Remember $REGN dropping after the DAYBREAK readout? Look at it now. Today’s results show why there’s still plenty of opportunity in retinal treatments. Kodiak has two more catalysts ahead and, if the data delivers, potential for a blockbuster. Still a long, bumpy road, but we’re in a much better position than when we were buying around $1.80 three years ago. Honestly, I’m glad retail overlooked this one. I’d rather follow clinical progress than another overhyped biotech ticker with millions of shares traded and endless 🚀 posts every day. Let’s see what the next two readouts bring. Bears might need some new material 😜
1 replies
Snackdaddy Oct 30, 7:49 PM
$KOD strongest stock in the market. refuses to be beat down buyout at $200
0 replies
spinusn27 Oct 30, 7:31 PM
$KOD Another great week in the books! Momentum is real, and the fundamentals back it up. DAYBREAK delivered positive Phase 3 results, Zenkuda is moving toward its BLA filing, and December's PEAK Phase 3 readout could bring the next round of fireworks. If December delivers and execution stays on track, I still believe $135+ by late January is very much in play. But let's not forget—this is biotech. One bad clinical surprise can change the picture overnight. That's about the only prayer the shorts have left, and with 8.5 million shares still short as of October 15, they haven't all thrown in the towel. My conviction hasn't changed: $150 before $50. That's my prediction, not a guarantee. The data will ultimately decide. Only time will tell. Good luck to everyone who's been here since the sub-$30 days. We've come a long way, and I believe the best may still be ahead. Let the science do the talking.
0 replies
Tom2772 Oct 30, 6:45 PM
$KOD $OTLK
1 replies
GZ4kdd Oct 30, 6:39 PM
$KOD 0 revenue, 0 product, dilution + cash burn, delays, with complete speculation at $100 😂vs $OTLK with current FDA approval and revenue, trading in the pennies, what is going on
1 replies
Tom2772 Oct 30, 6:25 PM
$OTLK $KOD $IOVA $IBRX Plus, 12 years of U.S. reference product exclusivity under the BPCIA We could also give this little detail about LYTENAVA some attention, couldn't we?
0 replies
GZ4kdd Oct 30, 5:58 PM
$KOD wonder how this is gonna stay up when they have shit earnings in 2 weeks time
1 replies